# Bio-Techne Corporation (TECH)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $8.39B  
**Price:** $52.50 (-3.51%)

> Bio-Techne Corporation is a global life sciences company that develops, manufactures, and supplies specialized tools for research and clinical diagnostics. The company focuses on high-quality reagents, analytical instruments, and precision diagnostic products used across pharmaceutical, biotechnology, academic, and clinical laboratory settings. Through its protein sciences activities, Bio-Techne provides antibodies, bioactive proteins, assays, and related instruments that support investigations into cellular pathways, disease mechanisms, and therapeutic targets. Its diagnostics and spatial biology offerings include diagnostic reagents, molecular diagnostic solutions, and advanced platforms for visualizing and quantifying biomolecules in tissues, supporting pathology and translational research. Bio-Techne serves a diversified customer base involved in drug discovery, basic and applied research, and high-complexity diagnostic testing, helping ensure reproducible and consistent experimental results. Incorporated in 1981 and headquartered in Minneapolis, Minnesota, Bio-Techne today plays a significant role in the global life sciences infrastructure by providing critical consumables and instruments that are embedded in laboratory workflows worldwide.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.22B | $790M | $102M | $73M | $0.46 |
| 2024 | $1.16B | $770M | $207M | $168M | $1.05 |
| 2023 | $1.14B | $770M | $299M | $285M | $1.76 |
| 2022 | $1.11B | $756M | $297M | $272M | $1.66 |
| 2021 | $931M | $633M | $237M | $140M | $0.87 |
| 2020 | $739M | $483M | $157M | $229M | $5.82 |
| 2019 | $714M | $473M | $147M | $96M | $2.47 |
| 2018 | $643M | $432M | $136M | $126M | $3.31 |
| 2017 | $563M | $375M | $121M | $76M | $2.03 |
| 2016 | $499M | $337M | $151M | $104M | $2.80 |
| 2015 | $452M | $307M | $147M | $108M | $2.89 |
| 2014 | $358M | $251M | $160M | $111M | $3.00 |
| 2013 | $311M | $231M | $158,469 | $113M | $3.05 |
| 2012 | $315M | $236M | $166M | $112M | $3.04 |
| 2011 | $290M | $225M | $163M | $112M | $3.02 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $2.56B | $639M | $1.92B | $162M | — |
| 2024 | $2.70B | $635M | $2.07B | $152M | — |
| 2023 | $2.64B | $672M | $1.97B | $181M | — |
| 2022 | $2.29B | $593M | $1.70B | $173M | — |
| 2021 | $2.26B | $700M | $1.56B | $199M | — |
| 2020 | $2.03B | $646M | $1.38B | $147M | — |
| 2019 | $1.88B | $719M | $1.17B | $101M | — |
| 2018 | $1.59B | $514M | $1.08B | $122M | — |
| 2017 | $1.56B | $609M | $950M | $92M | — |
| 2016 | $1.13B | $250M | $879M | $64M | — |
| 2015 | $1.06B | $216M | $847M | $55M | — |
| 2014 | $862M | $67M | $795M | $319M | — |
| 2013 | $778M | $41M | $738M | $164M | — |
| 2012 | $719M | $45M | $674M | $117M | — |
| 2011 | $618M | $32M | $586M | $78M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $288M | $31M | $257M |
| 2024 | $299M | $63M | $236M |
| 2023 | $254M | $38M | $216M |
| 2022 | $325M | $45M | $280M |
| 2021 | $352M | $44M | $308M |
| 2020 | $205M | $52M | $153M |
| 2019 | $182M | $25M | $156M |
| 2018 | $170M | $21M | $149M |
| 2017 | $144M | $15M | $129M |
| 2016 | $144M | $17M | $127M |
| 2013 | $124M | $22M | $101M |
| 2012 | $127M | $6M | $121M |
| 2011 | $127M | $4M | $124M |
| 2010 | $111M | $5M | $107M |
| 2009 | $111M | $7M | $105M |

Source: [CompaniesByCap](https://companiesbycap.com/company/TECH)